Syngenta's Hong Kong IPO Valued at Least $66 Billion, Poised to Be Next Year's Largest Global IPO
nashnova research
ChemChina-owned agrochemical giant Syngenta is targeting a Hong Kong IPO at no less than $66 billion, aiming to raise $5–10 billion — potentially the world's largest listing next year and the company's second attempt at going public.
How big is this IPO?
Lead underwriters UBS and CICC are marketing Syngenta at 15–20 times its projected 2026 EBITDA — earnings before interest, taxes, depreciation, and amortization, a standard gauge of operating profitability.
Based on a 2025 EBITDA of $4.4 billion, that puts the valuation range at roughly $66–88 billion.
This means → at the top end, Syngenta would be worth more than double the $43 billion ChemChina paid to acquire it in 2017.
Where does the money come from — and where does it go?
Syngenta plans to sell 10–20% of its equity, raising an estimated $5–10 billion.
Proceeds serve two purposes: paying down debt and funding its seeds and crop-protection businesses.
In plain terms = this is a "refinance and reinvest" deal — the company needs to lighten the debt load from its 2017 buyout while keeping its R&D pipeline funded.
Why price it like a biotech company?
Syngenta is positioning itself as a biotech enterprise, not a traditional chemical manufacturer.
The key assets justifying a premium valuation are its crop-protection portfolio and its pipeline of disease- and pest-resistant seed varieties.
This means → whether investors accept the "biotech" label will directly determine if the final price lands closer to $66 billion or $88 billion.
Why Hong Kong — and why now?
After ChemChina acquired Syngenta for $43 billion in 2017, the company filed to list on Shanghai's STAR Market but withdrew the application in 2024.
It now plans to list in Hong Kong, most likely in January 2027, though a late-2026 listing has not been ruled out.
This reflects a pivot after the A-share route stalled — Hong Kong offers a more predictable approval process for large multinational listings and broader access to international investors.
Who is running the deal?
UBS and CICC are lead underwriters; CITIC Bank and Bank of America are also in the syndicate.
This means → the mixed Chinese-and-Western banking lineup signals the IPO is targeting both international institutional investors and onshore Chinese channels — subscription appetite on each side will shape the final pricing.
市场有风险，内容仅供研究参考，不构成投资建议。